CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article


Fig. 4. Radicicol does not inhibit ERK phosphorylation. Cells were treated for 36–40 h with various concentrations of radicicol or MEK inhibitors in DMEM with 5% DCS. Whole cell extracts with equal amounts of total protein from these cells were analyzed by Western blotting for phosphorylation status of ERK. Blots were first probed with anti-phospho-ERK (top panels) and subsequently stripped and reprobed with antiERK (bottom panels). A, ras-transformed NIH3T3 cells B, MEK-1-S218D,S222D-infected NIH3T3 cells.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation